Biosimilar Development News
-
Zentiva And Lupin Sign License And Supply Agreement For TNF Alpha Inhibitor Biosimilar Medicine
7/9/2025
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin's biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.
-
Celltrion USA Announces U.S. Launch Of Denosumab Biosimilars, STOBOCLO® And OSENVELT® (denosumab-bmwo)
7/7/2025
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States.
-
Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
7/3/2025
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) has granted marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab.
-
Sunshine Biopharma Launches NIOPEG(R) Into $10B Biologics Market
7/2/2025
Sunshine Biopharma Inc. (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched NIOPEG, the Company's first Biosimilar drug on the market.
-
mAbxience Announces European Commission Approval Of Denosumab Biosimilars
7/2/2025
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce and Izamby.
-
Apotex Receives Health Canada Approval For Aflivu™, A Biosimilar To Eylea®, Available In Pre-Filled Syringe And Vial Formats
7/2/2025
Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
Fresenius Expands Biosimilars Portfolio With The Launch Of Denosumab Biosimilars In The US
7/1/2025
Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.
-
Alvotech And Advanz Pharma Enter Into European Supply And Commercialization Agreement For Biosimilar Candidate To Cimzia® (certolizumab pegol)
7/1/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia® (certolizumab pegol).
-
Bio Usawa Biotechnology And Bioeq AG Partner To Create Widespread Access To Vision-Saving Medicine Across Sub-Saharan Africa
7/1/2025
Bio Usawa Biotechnology Ltd. (Bio Usawa) and Bioeq AG today announced a groundbreaking agreement that will bring a life-changing biosimilar medicine—ranibizumab, used to treat serious retinal diseases—within reach for millions across Sub-Saharan Africa.
-
Sandoz Further Asserts Leadership In Biosimilars, Breaking Ground On New Slovenia Facility To Expand European Biosimilar Hub And Global Market Reach
7/1/2025
Sandoz, the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia.